Analyst Jason McCarthy of Maxim Group maintained a Buy rating on OS Therapies Incorporated, retaining the price target of $6.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jason McCarthy has given his Buy rating due to a combination of factors including the promising regulatory progress and the potential market impact of OS Therapies’ OST-HER2 treatment. The recent meeting with the Dutch Rapporteur has aligned key areas for a conditional marketing authorization submission, particularly highlighting the positive safety profile and sufficient non-clinical data. The efficacy data, while still needing further confirmation, shows encouraging signs with significant differences in survival rates compared to historical controls.
Additionally, the potential for label expansion through post-market confirmatory studies could enhance the treatment’s applicability and market reach. The OST-HER2’s designations, such as FDA Orphan and Fast Track, further strengthen its position by offering opportunities for priority review vouchers, which could provide substantial non-dilutive capital. These factors collectively contribute to a favorable outlook for OS Therapies, justifying the Buy rating.
According to TipRanks, McCarthy is an analyst with an average return of -11.6% and a 38.63% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as OS Therapies Incorporated, Atossa Therapeutics, and SCYNEXIS.